OTCMKTS:IPSEY - Ipsen Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$23.52
▼ -0.53 (-2.20%)
1 month | 3 months | 12 months
Get New Ipsen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPSEY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPSEY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Ipsen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $23.52.
Hold
The current consensus among 9 polled investment analysts is to hold stock in Ipsen. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
i
2/16/2021BarclaysReiterated RatingOverweight
i
1/14/2021Societe GeneraleUpgradeHold ➝ Buy
i
12/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
i
12/4/2020Bank of AmericaDowngradeBuy ➝ Neutral
i
12/2/2020Bryan, Garnier & CoDowngradeBuy ➝ Neutral
i
10/26/2020BarclaysUpgradeEqual Weight ➝ Overweight
i
9/1/2020Morgan StanleyReiterated RatingOverweight
i
8/4/2020UBS GroupReiterated RatingBuy
i
8/3/2020Credit Suisse GroupReiterated RatingNeutral
i
7/31/2020BarclaysReiterated RatingEqual Weight
i
7/22/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
7/16/2020Societe GeneraleDowngradeBuy ➝ Hold
i
7/14/2020Morgan StanleyReiterated RatingOverweight
i
6/1/2020BarclaysReiterated RatingEqual Weight
i
6/1/2020Bank of AmericaUpgradeNeutral ➝ Buy
i
5/18/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
4/22/2020UBS GroupReiterated RatingBuy
i
4/20/2020BarclaysReiterated RatingEqual Weight
i
2/11/2020Credit Suisse GroupUpgradeUnderperform ➝ Neutral
i
1/9/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
i
1/5/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
12/9/2019BarclaysDowngradeOverweight ➝ Equal Weight
i
5/20/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
2/19/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral
i
10/29/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform
i
10/8/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
9/28/2018The Goldman Sachs GroupInitiated CoverageSell
i
9/20/2017Societe GeneraleUpgradeHold ➝ Buy
i
9/19/2017Societe GeneraleUpgradeHold ➝ Buy
i
7/7/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
5/9/2016Morgan StanleyUpgradeEqual Weight ➝ Overweight
i
4/26/2016Jefferies Financial GroupUpgradeHold ➝ Buy
i
(Data available from 4/21/2016 forward)
Ipsen logo
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company offers drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, and Mucodyne. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
Read More

Today's Range

Now: $23.52
$23.42
$23.68

50 Day Range

MA: $21.25
$19.88
$24.05

52 Week Range

Now: $23.52
$16.79
$27.10

Volume

10,696 shs

Average Volume

3,276 shs

Market Capitalization

$7.89 billion

P/E Ratio

12.44

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Ipsen?

The following sell-side analysts have issued stock ratings on Ipsen in the last twelve months: Bank of America Co., Barclays PLC, Bryan, Garnier & Co, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Societe Generale, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for IPSEY.

What is the current price target for Ipsen?

0 Wall Street analysts have set twelve-month price targets for Ipsen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Ipsen in the next year.
View the latest price targets for IPSEY.

What is the current consensus analyst rating for Ipsen?

Ipsen currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IPSEY, but not buy more shares or sell existing shares.
View the latest ratings for IPSEY.

What other companies compete with Ipsen?

How do I contact Ipsen's investor relations team?

Ipsen's physical mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company's listed phone number is 33-01-58-33-50-00 and its investor relations email address is [email protected] The official website for Ipsen is www.ipsen.com.